{"id":53105,"date":"2026-01-06T22:00:23","date_gmt":"2026-01-06T14:00:23","guid":{"rendered":"https:\/\/flcube.com\/?p=53105"},"modified":"2026-01-06T22:00:24","modified_gmt":"2026-01-06T14:00:24","slug":"earendil-labs-partners-with-sanofi-on-2-56-billion-bispecific-antibody-deal-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53105","title":{"rendered":"Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases"},"content":{"rendered":"\n<p><strong>Earendil Labs<\/strong>, the overseas subsidiary of Helixon, announced a strategic collaboration with <strong>Sanofi (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>)<\/strong> to leverage its discovery platform for multiple autoimmune and inflammatory disease programs, with Sanofi leading development and worldwide commercialization of resulting bispecific antibody candidates. The deal, valued at up to <strong>USD\u202f2.56\u202fbillion<\/strong>, includes <strong>USD\u202f160\u202fmillion<\/strong> in upfront and near\u2011term payments and deepens a relationship that began with a <strong>USD\u202f125\u202fmillion upfront deal in April\u202f2025<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-collaboration-overview\">Collaboration Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Earendil Labs (Helixon overseas subsidiary)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Sanofi Inc. (NASDAQ: SNY)<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Earendil\u2019s bispecific antibody discovery platform<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Autoimmune and inflammatory diseases<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>Worldwide (Sanofi leads development &amp; commercialization)<\/td><\/tr><tr><td><strong>Financial Value<\/strong><\/td><td>Up to <strong>USD\u202f2.56\u202fbillion<\/strong><\/td><\/tr><tr><td><strong>Upfront\/Near\u2011Term Payments<\/strong><\/td><td><strong>USD\u202f160\u202fmillion<\/strong> tied to early achievements<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered up to <strong>low double\u2011digit percentage<\/strong> on net sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-previous-collaboration-foundation\">Previous Collaboration Foundation<\/h2>\n\n\n\n<p><strong>April\u202f2025 Agreement<\/strong>: Sanofi paid <strong>USD\u202f125\u202fmillion upfront<\/strong> to acquire exclusive global rights for <strong>HXN\u20111002 (\u03b14\u03b27\/TL1A)<\/strong> and <strong>HXN\u20111003 (TL1A\/IL\u201123)<\/strong>, two bispecific antibody candidates from Earendil.<\/p>\n\n\n\n<p><strong>Strategic Deepening<\/strong>: The new multi\u2011program collaboration expands the partnership beyond the initial two assets, validating Earendil\u2019s platform and Sanofi\u2019s commitment to building a <strong>dominant bispecific franchise<\/strong> in immunology.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-platform-technology-bispecific-discovery-engine\">Platform Technology: Bispecific Discovery Engine<\/h2>\n\n\n\n<p><strong>Earendil\u2019s Platform<\/strong>: Proprietary technology enables <strong>rapid generation of bispecific antibodies<\/strong> targeting two distinct pathways (e.g., integrin\u2011\u03b14\u03b27 + TL1A; TL1A + IL\u201123) with <strong>optimized avidity<\/strong> and <strong>reduced immunogenicity<\/strong>.<\/p>\n\n\n\n<p><strong>Key Advantages<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Pathway Blockade<\/strong>: Addresses <strong>complex inflammatory cascades<\/strong> more effectively than monotherapies<\/li>\n\n\n\n<li><strong>Lower Dosing<\/strong>: Synergistic effects enable <strong>sub\u2011cutaneous administration<\/strong> with <strong>improved patient compliance<\/strong><\/li>\n\n\n\n<li><strong>Pipeline Velocity<\/strong>: Reduces discovery timeline from <strong>24\u201136 months to 12\u201118 months<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-autoimmune-amp-inflammatory-diseases\">Market Opportunity: Autoimmune &amp; Inflammatory Diseases<\/h2>\n\n\n\n<p><strong>Global Market<\/strong>: <strong>\u00a52.8\u202ftrillion<\/strong> (US$390\u202fbillion) in 2025, growing at <strong>8% CAGR<\/strong>, driven by <strong>Crohn\u2019s disease, ulcerative colitis, psoriasis, and lupus<\/strong>.<\/p>\n\n\n\n<p><strong>Unmet Need<\/strong>: <strong>30\u201140%<\/strong> of patients fail to respond to existing biologics (anti\u2011TNF, anti\u2011IL\u201112\/23), creating demand for <strong>next\u2011generation bispecifics<\/strong>.<\/p>\n\n\n\n<p><strong>Sanofi\u2019s Immunology Portfolio<\/strong>: The collaboration strengthens Sanofi\u2019s <strong>Dupixent (IL\u20114\/13) leadership<\/strong> and builds a <strong>second\u2011generation pipeline<\/strong> to defend against biosimilar competition post\u20112027.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-amp-commercialization-pathway\">Development &amp; Commercialization Pathway<\/h2>\n\n\n\n<p><strong>Earendil\u2019s Role<\/strong>: Lead discovery through <strong>IND\u2011enabling studies<\/strong>, leveraging <strong>USD\u202f160\u202fmillion<\/strong> in near\u2011term funding.<\/p>\n\n\n\n<p><strong>Sanofi\u2019s Role<\/strong>: Assume full responsibility for <strong>global clinical development, regulatory submissions, and commercialization<\/strong> upon candidate selection.<\/p>\n\n\n\n<p><strong>Milestone Structure<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Discovery Milestones<\/strong>: USD\u202f50\u202fmillion (candidate nomination)<\/li>\n\n\n\n<li><strong>Development Milestones<\/strong>: USD\u202f1.8\u202fbillion (Phase\u202fI\u2011III completions)<\/li>\n\n\n\n<li><strong>Commercial Milestones<\/strong>: USD\u202f500\u202fmillion (sales thresholds)<\/li>\n\n\n\n<li><strong>Royalties<\/strong>: Low double\u2011digit tiered royalties post\u2011launch<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Platform<\/th><th>Bispecific Focus<\/th><th>Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>Earendil + Sanofi<\/strong><\/td><td>Proprietary<\/td><td>TL1A, \u03b14\u03b27, IL\u201123, undisclosed targets<\/td><td>Discovery \u2192 Phase\u202fIII<\/td><\/tr><tr><td><strong>Pfizer<\/strong><\/td><td>Modular formats<\/td><td>IL\u201115\/IL\u201121, TNF\/IL\u201117<\/td><td>Phase\u202fII<\/td><\/tr><tr><td><strong>Roche<\/strong><\/td><td>Two\u2011in\u2011one<\/td><td>IL\u20116\/IL\u201121, TNF\/IL\u201123<\/td><td>Phase\u202fI\/II<\/td><\/tr><tr><td><strong>AbbVie<\/strong><\/td><td>DVD\u2011Ig<\/td><td>JAK\/TL1A, TNF\/IL\u201123<\/td><td>Pre\u2011clinical<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Moat<\/strong>: Earendil\u2019s <strong>irreversible conjugation technology<\/strong> and <strong>rapid discovery engine<\/strong> provide <strong>12\u201118 month lead time<\/strong> vs. competitors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact-amp-valuation\">Financial Impact &amp; Valuation<\/h2>\n\n\n\n<p><strong>Earendil (Helixon) Upside<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immediate Cash<\/strong>: USD\u202f160\u202fmillion strengthens balance sheet<\/li>\n\n\n\n<li><strong>Milestone Potential<\/strong>: USD\u202f2.4\u202fbillion in remaining milestones<\/li>\n\n\n\n<li><strong>Royalty Stream<\/strong>: Est. <strong>USD\u202f300\u2011500\u202fmillion<\/strong> annually by 2032 at peak sales<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Enables <strong>additional partnerships<\/strong> beyond Sanofi<\/li>\n<\/ul>\n\n\n\n<p><strong>Sanofi\u2019s ROI<\/strong>: Access to <strong>4\u20116 bispecific candidates<\/strong> at <strong>~USD\u202f400\u2011500\u202fmillion<\/strong> per asset (vs. internal development cost of <strong>USD\u202f1\u20111.5\u202fbillion<\/strong>).<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding milestone achievements, clinical timelines, and market penetration for Earendil\u2019s bispecific platform. Actual results may differ materially due to clinical trial outcomes, competitive responses, and regulatory acceptance of novel mechanisms.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Earendil Labs, the overseas subsidiary of Helixon, announced a strategic collaboration with Sanofi (NASDAQ: SNY)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53107,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,4017,3904,867,147],"class_list":["post-53105","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-auto-immune","tag-earendil-labs","tag-helixon","tag-nasdaq-sny","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Earendil Labs, the overseas subsidiary of Helixon, announced a strategic collaboration with Sanofi (NASDAQ: SNY) to leverage its discovery platform for multiple autoimmune and inflammatory disease programs, with Sanofi leading development and worldwide commercialization of resulting bispecific antibody candidates. The deal, valued at up to USD\u202f2.56\u202fbillion, includes USD\u202f160\u202fmillion in upfront and near\u2011term payments and deepens a relationship that began with a USD\u202f125\u202fmillion upfront deal in April\u202f2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53105\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases\" \/>\n<meta property=\"og:description\" content=\"Earendil Labs, the overseas subsidiary of Helixon, announced a strategic collaboration with Sanofi (NASDAQ: SNY) to leverage its discovery platform for multiple autoimmune and inflammatory disease programs, with Sanofi leading development and worldwide commercialization of resulting bispecific antibody candidates. The deal, valued at up to USD\u202f2.56\u202fbillion, includes USD\u202f160\u202fmillion in upfront and near\u2011term payments and deepens a relationship that began with a USD\u202f125\u202fmillion upfront deal in April\u202f2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53105\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-06T14:00:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-06T14:00:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0603-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53105#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53105\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases\",\"datePublished\":\"2026-01-06T14:00:23+00:00\",\"dateModified\":\"2026-01-06T14:00:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53105\"},\"wordCount\":577,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53105#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0603-1.webp\",\"keywords\":[\"Auto-immune\",\"Earendil Labs\",\"Helixon\",\"NASDAQ: SNY\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53105#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53105\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53105\",\"name\":\"Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53105#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53105#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0603-1.webp\",\"datePublished\":\"2026-01-06T14:00:23+00:00\",\"dateModified\":\"2026-01-06T14:00:24+00:00\",\"description\":\"Earendil Labs, the overseas subsidiary of Helixon, announced a strategic collaboration with Sanofi (NASDAQ: SNY) to leverage its discovery platform for multiple autoimmune and inflammatory disease programs, with Sanofi leading development and worldwide commercialization of resulting bispecific antibody candidates. The deal, valued at up to USD\u202f2.56\u202fbillion, includes USD\u202f160\u202fmillion in upfront and near\u2011term payments and deepens a relationship that began with a USD\u202f125\u202fmillion upfront deal in April\u202f2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53105#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53105\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53105#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0603-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0603-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53105#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Earendil Labs, the overseas subsidiary of Helixon, announced a strategic collaboration with Sanofi (NASDAQ: SNY) to leverage its discovery platform for multiple autoimmune and inflammatory disease programs, with Sanofi leading development and worldwide commercialization of resulting bispecific antibody candidates. The deal, valued at up to USD\u202f2.56\u202fbillion, includes USD\u202f160\u202fmillion in upfront and near\u2011term payments and deepens a relationship that began with a USD\u202f125\u202fmillion upfront deal in April\u202f2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53105","og_locale":"en_US","og_type":"article","og_title":"Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases","og_description":"Earendil Labs, the overseas subsidiary of Helixon, announced a strategic collaboration with Sanofi (NASDAQ: SNY) to leverage its discovery platform for multiple autoimmune and inflammatory disease programs, with Sanofi leading development and worldwide commercialization of resulting bispecific antibody candidates. The deal, valued at up to USD\u202f2.56\u202fbillion, includes USD\u202f160\u202fmillion in upfront and near\u2011term payments and deepens a relationship that began with a USD\u202f125\u202fmillion upfront deal in April\u202f2025.","og_url":"https:\/\/flcube.com\/?p=53105","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-06T14:00:23+00:00","article_modified_time":"2026-01-06T14:00:24+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0603-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53105#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53105"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases","datePublished":"2026-01-06T14:00:23+00:00","dateModified":"2026-01-06T14:00:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53105"},"wordCount":577,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53105#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0603-1.webp","keywords":["Auto-immune","Earendil Labs","Helixon","NASDAQ: SNY","Sanofi"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53105#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53105","url":"https:\/\/flcube.com\/?p=53105","name":"Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53105#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53105#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0603-1.webp","datePublished":"2026-01-06T14:00:23+00:00","dateModified":"2026-01-06T14:00:24+00:00","description":"Earendil Labs, the overseas subsidiary of Helixon, announced a strategic collaboration with Sanofi (NASDAQ: SNY) to leverage its discovery platform for multiple autoimmune and inflammatory disease programs, with Sanofi leading development and worldwide commercialization of resulting bispecific antibody candidates. The deal, valued at up to USD\u202f2.56\u202fbillion, includes USD\u202f160\u202fmillion in upfront and near\u2011term payments and deepens a relationship that began with a USD\u202f125\u202fmillion upfront deal in April\u202f2025.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53105#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53105"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53105#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0603-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0603-1.webp","width":1080,"height":608,"caption":"Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53105#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0603-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53105","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53105"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53105\/revisions"}],"predecessor-version":[{"id":53108,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53105\/revisions\/53108"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53107"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53105"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53105"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53105"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}